TriangleCART (NCT07319676)
CART trial for B-cell Lymphoma Refractory (NCT07319676). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
CAR T cells against CD19 have changed the outlook for relapsed B-cell lymphoma. But after rounds of chemotherapy, a patient's T cells are worn down, and the engineered cells may fail to expand.
The idea: give the cells a receptor for a growth signal the body already makes.
At National University Hospital in Singapore, a patient's T cells receive the CD19 receptor together with a receptor for erythropoietin, the hormone that drives red blood cell production, so natural or supplemental erythropoietin can feed the T cells too. If the biopsy shows CD22 as well, a second CAR T product is added, making escape harder.
A safety study leading into phase two, ages ten to eighty. Michelle Poon leads it. Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.